AI is now well entrenched in the public mind, as ChatGPT has so effectively shown. Because of this, we weren't too surprised when a large number of investors told us they now hardly ever see a biotech firm without using AI in some way.
Francisco Dopazo, a general partner at Humboldt Fund, recently told TechCrunch that "most of the firms we have seen include an AI component to enhance the discovery or development processes."
However, despite becoming a popular catchphrase, transaction flow and valuations in the biotech industry aren't being increased by AI's seeming ubiquity. We therefore asked six investors what they look for in a biotech firm today in order to better understand how AI will effect biotech in 2022.
